ArticleScientific reports2025
Optimization of low-temperature nitrogen plasma in reducing fungi and aflatoxin human exposure through maize.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A New Frontier in Food Safety: Cold Plasma Strategies for Effective Control of Fungi and Mycotoxins.Toxins · 2026Review
- Agroecological drivers of aflatoxin contamination in maize-based systems: a review.Frontiers in plant science · 2026Review
- Modelling the Combined Effects of Oxalic Acid, Water Activity, and pH on the Growth and Mycotoxin Production ofFoods (Basel, Switzerland) · 2025Article
- Low-Temperature Degradation of Aflatoxins via Oxygen Plasma: Kinetics and Mechanism Driven by Atomic Oxygen Flux.Materials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Globally, aflatoxin contamination in maize remains a huge burden despite many interventions put in place. The use of low-temperature plasma to decontaminate the maize is a potential solution for ensuring the safety and extended shelf life of the grain. This study optimized the parameters and investigated the efficacy of low-temperature nitrogen plasma (LTNP) in destroying fungi and reducing exposure to aflatoxins in naturally contaminated maize from an endemic region. The study generated 17 experimental runs using the Response Surface Methodology (RSM) of the Box Behnken Design (BBD) with exposure time, pressure, and ionization density as independent variables. Quantitative exposure assessment was conducted using Monte Carlo simulations followed by sensitivity and scenario analysis to study factors influencing exposure and best aflatoxin-reducing plasma parameters. The best-fitting RSM model, the linear model, indicated that increased exposure time but not pressure and power led to a corresponding statistically significant decrease in the fungal load and aflatoxin content. LTNP reduced aflatoxin contamination to levels below all the main global regulatory limits. Numerical optimization of the percent reduction in aflatoxin and fungal load indicated that an exposure time of 1793.4 s, pressure of 0.98 pascal and ionization power of 189.8 W are required to achieve an optimal reduction of aflatoxin content of 82.6% and fungal load of 96.9%. Exposure assessment indicated high exposure especially for populations with lower body weight with ρ = -0.46 between body weight and exposure. The best LTNP combinations achieved aflatoxin exposure reduction results comparable to but with markedly less variation than existing practically used decontamination methods. Further optimization studies during upscaling are recommended, incorporating independent factors such as temperature and processing volume and outcomes such as organoleptic, physical, and chemical changes in the food matrices after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.